- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03195855
Foot and Ankle Mobilisation in Diabetic Peripheral Neuropathy
The Effects of Foot and Ankle Joint Mobilisation Combined With a Home Programme of Ankle Stretches on Joint Range of Motion and Forefoot Peak Plantar Pressures in People With Diabetic Peripheral Neuropathy: a Randomized Controlled Trial
Diabetes can affect the blood supply to the nerves in the legs. When this occurs a peripheral neuropathy can occur when the nerves carrying sensory information are affected. People with diabetic peripheral neuropathy have a high risk of foot ulceration and amputation which affects function and associated with high NHS and social care costs. People with diabetes can also have reduced movement at joints caused by increased stiffness in connective tissue. Reductions in ankle and big toe movement leads to increases in the pressure over the sole on the front part of the foot (the forefoot) when walking; this is a risk factor for ulceration.
The study will to assess whether ankle and big toe joint mobilisations and home program of stretches in people with diabetic peripheral neuropathy improves joint range of motion and reduces forefoot peak pressures.
Fifty eight people with diabetic peripheral neuropathy and a moderate risk of plantar ulceration will be recruited from a local podiatry clinic. They will be randomly assigned to an intervention (29 people) or control group (29 people). We will control for between-group differences in age using a minimization process. The intervention will consist of a 6 week program of ankle and big toe joint mobilisation by a physiotherapist and home stretches. The control group will consist of usual care including podiatry interventions.
Outcome measures will be taken at baseline, post intervention and at 3 month follow up by an assessor who does not know the group allocation. Primary outcome will be ankle range while walking with secondary outcomes including big toe joint range, forefoot pressure while walking and balance.
Changes over time between the groups will be compared statistically and the relationship between ankle range of motion and peak plantar pressure will be analysed using linear regression.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Plymouth, United Kingdom, PL4 7PY
- Livewell Southwest
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of type I or II diabetes with a moderate risk of foot ulceration as defined by i. Detection in less than <8/10 sites on the plantar aspect of the foot using a 10 g monofilament ii. Foot deformity defined and graded using a foot deformity score previously developed for people with diabetes (54) (Attached)
- Peripheral Neuropathy- This is defined according to NICE CG19 guidelines. Here, the ability to detect a 10g monofilament (Owen Mumford "neuropen", UK) at 5 sites per foot on the plantar aspect of the toes (1,3 and 5) and metatarsophalangeal joints (1 and 5) is tested. No feeling in less than 8 sites indicates increased risk of foot ulceration (55)
- Ankle joint stiffness: Static, non-weight bearing ankle dorsiflexion will be measured using goniometry (56). Ankle joint stiffness will be defined as 0 or less ankle dorsiflexion (14, 57) due to recent evidence that these patients are more likely to exhibit limited ankle dorsiflexion of <10 degrees during gait (58).
- Hallux joint stiffness (hallux limitus): Hallux dorsiflexion will be measured using goniometry and will be defined as <10 degrees of available dorsiflexion at the hallux during weight bearing (59, 60).
- Able to walk for 10 meters with or without using a walking aid
- Able to attend 6 sessions over a 6 week period
- Age >18 yrs
Exclusion Criteria:
- Plantar Ulceration: People with a current ulceration will be excluded from the study.
- Rheumatoid arthritis, ankle and 1st MTP osteoarthritis or Dupuytren's contractures as determined from medical notes and participants subjective response.
- Excessive distal lower limb oedema preventing mobilisation rated visually according to criteria (63). People with >+2 pitting oedema in whom it is not possible to palpate the joint line will also be excluded from the study.
- History of lower limb injury in the past three months, or leg fracture/surgery in last year
- Osteoporosis as determined by the medical notes
- Prolonged (>1 yr.) history of steroid use
- Major amputation of lower limb
- Minor foot digits amputation
- Charcot arthropathy - both stages of acute (determined by the clinical signs of unilateral swelling, elevated skin temperature, erythema and joint effusion in the foot or ankle (61)) and chronic.
- Additional neurological or oncological conditions affecting the lower limb
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Ankle and big toe mobilisations combined with home stretches
Intervention group (n=29): This group will undertake talocural and 1st MTP joint mobilisations (x1/week for 6 weeks) and a 6 week home programme of stretching exercises.
|
Manual therapy is a common form of treatment employed usually by physiotherapists, in order to help increase range of motion of a specific joint region by restoring the arthrokinematic accessory gliding and rolling movement that is associated with normal joint movement.
The hypothesised mechanism of action for this is that improvements of gliding and rolling will normalise osteokinematic rotation and consequently enable the normalisation of active movements.
Another possible mechanism of action of mobilisations includes increasing the extensibility of the noncontractile capsular and ligamentous tissues.
The effectiveness of passive accessory gliding techniques to increase joint ROM has been widely explored in the literature; with some studies revealing an increase in ankle dorsiflexion and others no change in ankle dorsiflexion.
However, the subjects taking part in these studies were people without diabetes and mostly people with ankle sprains or ankle instability.
Other Names:
|
|
NO_INTERVENTION: Control group of usual care including podiatry
Control group (n=29): Usual care including regular monitoring of foot health by podiatrists as indicated by NICE (NG19) guidelines (78). A review of current clinical practice within the podiatry clinic indicates that people with moderate/intermediate risk are reviewed every 3 months. Interventions include nail care, callus debridement and foot care advice. In both groups, interventions delivered by podiatrists in the study period will be determined from the clinic notes. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in maximum ankle range of dorsiflexion in stance phase when both feet are in contact with the ground (double support phase).
Time Frame: The change of maximum dorsiflexion between immediate treatment effects (week 6) and at 3-months post intervention follow-up period (week 18).
|
The change of maximum dorsiflexion between immediate treatment effects (week 6) and at 3-months post intervention follow-up period (week 18).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in maximum ankle dorsiflexion during swing phase of walking as measured by 3D motion analysis.
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
|
|
Change in total ankle range of motion during the stance phase of walking as measured by 3D motion analysis
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
|
|
Walking forefoot peak plantar pressures will be measured using an in-shoe system (F Scan UK)
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
|
|
Change in maximum static ankle dorsiflexion range
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
|
|
Change in maximum 1st MTP dorsiflexion range in quiet standing
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
|
|
Walking speed -maximal walking speed over 10 m
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
|
|
Stride length
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
|
|
Walking ability
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
12 item walking scale
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
|
Change in postural sway
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
Postural sway will me measured with posturography
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
|
Change in functional reach test
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
Functional reach test will be measured using a yardstick mounted on the wall at shoulder height
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To investigate the relationship between changes in static and dynamic ankle ROM
Time Frame: The following measures will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18
|
Linear association between change in static ankle ROM and dynamic ankle ROM
|
The following measures will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18
|
|
To investigate the relationship between changes in ankle ROM and balance
Time Frame: The following measures will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18)
|
Linear association between change in static ankle ROM and postural sway
|
The following measures will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18)
|
|
To investigate the compliance/adherence rates of the home exercise programme
Time Frame: The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
Home exercise sheets diary; this will indicate any daily stretches that are undertaken, the frequency (number per day) and total duration of stretching.
An open question will encourage participants to indicate any additional comments to give insight into the thinking behind why people chose to complete or not complete the stretches.The interview schedule will be generated from the recurrent themes (such as attitudes, behaviours, motivations or views on exercise) identified from the comments the participants made whilst filling in their foot and ankle exercise diaries.
|
The following measure will be taken at across two time periods: i) immediate effects after the intervention (change between week 0-6) and ii) 3-month post intervention follow up period (change between week 0-18).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vasileios Lepesis, Plymouth University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FHHS-228115-VL-026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Peripheral Neuropathy
-
Riphah International UniversityNot yet recruitingDiabetic Peripheral NeuropathyPakistan
-
Montiha AzeemRecruitingDiabetic Peripheral NeuropathyPakistan
-
Beni-Suef UniversityNot yet recruitingDiabetic Peripheral NeuropathyEgypt
-
Ain Shams UniversityRecruitingDiabetic Peripheral Neuropathy | Diabetic Neuropathy | Diabetic Peripheral Neuropathy in Type 2 Diabetic PatientsEgypt
-
University of FaisalabadActive, not recruitingDiabetic Peripheral NeuropathyPakistan
-
Lisa GriffinRecruitingHealthy Aging | Diabetic Peripheral Neuropathy | Diabetic Peripheral Neuropathy Type 2 | Diabetic Peripheral Neuropathy Type 2 - UncontrolledUnited States
-
Min LongRecruiting
-
Riphah International UniversityRecruitingDiabetic Peripheral Neuropathy (DPN)Pakistan
-
Pamlab, L.L.C.HealthCore, Inc.CompletedDiabetic Peripheral Neuropathy (DPN)United States
-
The First Affiliated Hospital of Zhejiang Chinese...The Third Affiliated hospital of Zhejiang Chinese Medical UniversityNot yet recruitingElectroacupuncture | Diabetic Peripheral Neuropathy (DPN)
Clinical Trials on Manual therapy / joint mobilisations
-
Royal Brompton & Harefield NHS Foundation TrustCompletedCystic FibrosisUnited Kingdom
-
Edinburgh Napier UniversityScottish Hospital Endowments Research Trust; Pacla Medical LtdCompletedLower Back PainUnited Kingdom
-
Jennifer Moreno ClinicUnknownKnee Osteoarthritis | Muscle Weakness | Muscle Weakness Condition | Knee Arthritis | Knee Pain Chronic | Knee Pain Swelling | Knee Deformity | PowerUnited States
-
Royal United Hospitals Bath NHS Foundation TrustCompleted
-
Loma Linda UniversityCompletedHemiparesis;Poststroke/CVAUnited States
-
Radboud University Medical CenterCompleted
-
The Taylor CollaborationWilma Chan Highland Hospital CampusNot yet recruitingKnee Arthritis | Knee Arthropathy
-
Washington University School of MedicineFoundation for Physical Therapy, Inc.Active, not recruitingFemoroacetabular Impingement | Hip-related Groin Pain | Dysplasia Mild | Prearthritic Hip DisorderUnited States
-
Federal University of Health Science of Porto AlegreTerminatedLow Back Pain | Mechanical Low Back Pain | BackacheBrazil